Co-Diagnostics Inc (CODX)
$10.54 0.38 (3.74%)
19:59 EST CODX Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 129.92M
PE Ratio -17.18
Volume (Avg. Vol.) 2.09M
Day's Range 10.36 - 11.18
52-Week Range 1.07 - 30.99
Dividend & Yield N/A (N/A)
CODX Stock Predictions, Articles, and Co-Diagnostics Inc News
- From InvestorPlace
- From the Web
By Ian Cooper
With a desperate need for more test test kits for the novel coronavirus, shares of CODX stock could continue to trend higher.
Co-Diagnostics will be on the move over the next week. Don't confuse a technical trade for a strong long-term investment case in CODX stock.
Monday's lawsuit hasn't impacted the chart of Co-Diagnostics one bit. Here are the price levels in CODX stock that I'd trade around right now.
CODX stock will start to tumble back to earth as more competitors enter the testing space, and the impact of Covid-19 subsides.
These seven A- and B-rated names are some of the top risky stocks to buy for enterprising investors. Here's what you should know about each company.
CODX stock took a hit as economic indicators suggested a sooner-than-expected recovery. But don’t completely ignore shares just yet.
The price target for CODX stock has been raised, but the testing-kit leader should easily clear the bar. More upside ahead.
The rush to develop a COVID-19 diagnostic test has pushed CODX stock to new highs. But investors may need more scientific evidence to stay in the shares long-term.
CODX stock could continue delivering upside if its novel coronavirus test kit proves accurate and vaccines take awhile to come to market.
From an investment standpoint, I’m always thinking about my options. I don’t necessarily have to invest in CODX stock because there are other potential options available, ones probably safer in the grand scheme of things.
The fear of missing out is a real stock price driver. Add to it the fear of the virus and you get unlimited upside potential for CODX stock.
There's evidence that Co-Diagnostics' test is not as accurate as many of its competitors' offerings. That makes CODX stock quite risky.
Co-Diagnostics may be worth much more than today's price. CODX stock could be worth two or three times more, under certain estimates.
Co-Diagnostics benefits from the quantity and quality of its test kits. This means CODX stock should long be one of investors' favorites.
Biotech stocks are in the spotlight in 2020, with the race to develop testing, treatment and a vaccine for Covid-19 driving rapid growth.
We're starting to see some light at the end of the coronavirus tunnel, and investors are looking at stocks to buy for a post-crisis bump.
Co-Diagnostics has seen its business explode because of the coronavirus pandemic and CODX stock is up over 1800% so far in 2020.
The last thing you need in your portfolio is a drastically volatile asset. Avoid CODX stock in both short- and long-term trades.
After a dreadful earnings report and conference call, the good times are over for Co-Diagnostics. CODX stock will continue to sink in coming days.
Co-Diagnostics stock has emerged as a big winner from Covid-19. Testing for novel viruses may make it a long-term winner in the new normal.
From Market News Video
Investors in Co-Diagnostics Inc (CODX) saw new options become available today, for the February 2021 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CODX options chain for the new February 2021 contracts and identified one put and one call contract of particular interest.
Navellier RatingsPowered by Portfolio Grader